MannKind Corp
MNKD
#4917
Rank
$1.74 B
Marketcap
$5.68
Share price
-0.53%
Change (1 day)
-15.60%
Change (1 year)

P/E ratio for MannKind Corp (MNKD)

P/E ratio as of December 2025 (TTM): 56.8

According to MannKind Corp's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 56.8. At the end of 2024 the company had a P/E ratio of 64.3.

P/E ratio history for MannKind Corp from 2004 to 2025

PE ratio at the end of each year

Year P/E ratio Change
202464.3
2022-15.513.5%
2021-13.79.08%
2020-12.5162.05%
2019-4.78
2017-2.09-182.3%
20162.54-255.88%
2015-1.63-84.08%
2014-10.225.97%
2013-8.13234.15%
2012-2.4328.39%
2011-1.89

P/E ratio for similar companies or competitors

Company P/E ratio P/E ratio differencediff. Country
Halozyme Therapeutics
HALO
13.0-77.08%๐Ÿ‡บ๐Ÿ‡ธ USA
Novo Nordisk
NVO
13.7-75.87%๐Ÿ‡ฉ๐Ÿ‡ฐ Denmark
Merck
MRK
13.2-76.83%๐Ÿ‡บ๐Ÿ‡ธ USA
Eli Lilly
LLY
49.0-13.68%๐Ÿ‡บ๐Ÿ‡ธ USA
Nektar Therapeutics
NKTR
-13.4-123.56%๐Ÿ‡บ๐Ÿ‡ธ USA
Pfizer
PFE
15.1-73.36%๐Ÿ‡บ๐Ÿ‡ธ USA

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.